Human CXCL13/BLC/BCA-1 Antibody

Catalog #: MAB801
17 Citations 3 Reviews Datasheet

Catalog #	Availability	Size / Price	Qty
MAB801-SP
MAB801-100
MAB801-500

Detection of Recombinant Human CXCL13/BLC/BCA‑1 by Western Blot.

2 Images

All CXCL13/BLC/BCA-1 Antibodies

Product Details

Citations (17)

FAQs

Supplemental Products

Reviews (3)

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CXCL13/BLC/BCA-1 Antibody Summary

Species Reactivity

Human

Specificity

Detects human CXCL13/BLC/BCA-1 in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant human (rh) CXCL1, rhCXCL2, rhCXCL3, rhCXCL8/IL‑8, rhCXCL10, rhCXCL9, rhCXCL12/SDF‑1 alpha, or rhCXCL12/SDF‑1 beta is observed. In Western blots, no cross‑reactivity with recombinant mouse CXCL13/BLC/BCA-1 is observed.

Source

Monoclonal Mouse IgG₁ Clone # 53610

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

E. coli-derived recombinant human CXCL13/BLC/BCA-1
Val23-Arg94
Accession # O43927

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

See below

Human CXCL13/BLC/BCA-1 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

2-8 µg/mL

Use in combination with:

Detection Reagent: Human CXCL13/BLC/BCA‑1 Biotinylated Antibody (Catalog # BAF801)

Standard: Recombinant Human CXCL13/BLC/BCA-1 Protein (Catalog # 801-CX)

Neutralization

Measured by its ability to neutralize CXCL13/BLC/BCA‑1-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR5. The Neutralization Dose (ND₅₀) is typically 0.3-0.9 µg/mL in the presence of 0.05 µg/mL Recombinant Human CXCL13/BLC/BCA‑1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Recombinant Human CXCL13/BLC/BCA‑1 by Western Blot. Western blot shows 100 ng of Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) and Recombinant Mouse CXCL13/BLC/BCA-1 (Catalog # 470-BC). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL13/BLC/BCA-1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.

Neutralization

View Larger

Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody. Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Anti-Human CXCL13/BLC/BCA-1 (0.05 µg/mL) is neutralized (green line) by increasing concentrations of Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801). The ND₅₀ is typically 0.3-0.9 µg/mL.

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL13/BLC/BCA-1

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

References

Gunn, M.D. et al. (1998) Nature, 391:799.
Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
Forster, R. et al. (1996) Cell 87:1037.

Entrez Gene IDs

10563 (Human); 55985 (Mouse)

Alternate Names

ANGIE; ANGIE2; B cell-attracting chemokine 1; B lymphocyte chemoattractant; BCA1; BCA-1; BCA1B-cell chemoattractant; BCA-1CXC chemokine BLC; B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1); BLC; BLCSmall-inducible cytokine B13; BLR1L; B-lymphocyte chemoattractant; chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); chemokine (C-X-C motif) ligand 13; C-X-C motif chemokine 13; CXCL13; SCYB13; SCYB13B-cell-attracting chemokine 1; small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Product Datasheets

Product Datasheet

Related Research Areas

Citations for Human CXCL13/BLC/BCA-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

17 Citations: Showing 1 - 10
Filter your results:

Filter by:

Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
Authors: Komori M, Blake A, Greenwood M et al.
Ann Neurol
Belatacept inhibit human B cell germinal center development in immunodeficient mice
Authors: Samson, C;Thiolat, A;Moktefi, A;Cohen, JL;Pilon, C;Grimbert, P;
Scientific reports
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC
The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astrocytoma
Authors: Shu-Jyuan Chang, Chia-Te Chao, Aij-Lie Kwan, Chee-Yin Chai
Pathology and Oncology Research
Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases
Authors: A Satou, T Tabata, H Miyoshi, K Kohno, Y Suzuki, D Yamashita, K Shimada, T Kawasaki, Y Sato, T Yoshino, K Ohshima, T Takahara, T Tsuzuki, S Nakamura
Mod. Pathol., 2019-04-05;0(0):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification
Authors: R Muto, H Miyoshi, K Sato, T Furuta, H Muta, K Kawamoto, E Yanagida, K Yamada, K Ohshima
Cancer Med, 2018-10-11;0(0):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Authors: DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, A Kiialainen, J Hanhart, C Schill, C Hess, S Savic Prin, M Wiese, D Lardinois, PC Ho, C Klein, V Karanikas, KD Mertz, TN Schumacher, A Zippelius
Nat. Med., 2018-06-11;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
Diminished CXCR5 expression in peripheral blood of patients with Sjï¿½gren's syndrome may relate to both genotype and salivary gland homing
Authors: LA Aqrawi, M Ivanchenko, A Björk, JI Ramírez Se, J Imgenberg-, M Kvarnström, P Haselmayer, JL Jensen, G Nordmark, K Chemin, K Skarstein, M Wahren-Her
Clin. Exp. Immunol., 2018-03-24;0(0):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC
Authors: A Asai, Y Tsuchimoto, H Ohama, S Fukunishi, Y Tsuda, M Kobayashi, K Higuchi, F Suzuki
Oncoimmunology, 2017-03-03;6(4):e1299301.
Species: Human
Sample Types: Whole Cells
Applications: ICC
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
Authors: Mika Komori, Yen Chih Lin, Irene Cortese, Andrew Blake, Joan Ohayon, Jamie Cherup et al.
Annals of Clinical and Translational Neurology
The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
Authors: Seok Jin Kim, Kyung Ju Ryu, Mineui Hong, Young Hyeh Ko, Won Seog Kim
Journal of Hematology & Oncology

CXCL13 antibody for the treatment of autoimmune disorders.
Authors: Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith E, Zauderer M
BMC Immunol, 2015-02-12;16(0):6.
Species: Human
Sample Types: Recombinant Protein
Applications: Direct ELISA

Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis.
Authors: Edwards, Keith R, Goyal, Jaya, Plavina, Tatiana, Czerkowicz, Julie, Goelz, Susan, Ranger, Ann, Cadavid, Diego, Browning, Jeffrey
PLoS ONE, 2013-11-20;8(11):e81007.
Species: Human
Sample Types: CSF
Applications: Immuno-PCR

Aberrant expression of selectin E, CXCL1, and CXCL13 in chronic endometritis
Authors: Kotaro Kitaya, Tadahiro Yasuo
Modern Pathology

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
Authors: Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kroger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D
Br. J. Cancer, 2008-09-16;99(6):930-8.
Species: Human
Sample Types: Cell Lysates, Whole Tissue
Applications: IHC-P, Western Blot

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
Authors: Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA
Blood, 2007-07-25;110(9):3316-25.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P

Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54.
Authors: Lisignoli G, Cristino S, Piacentini A, Cavallo C, Caplan AI, Facchini A
J. Cell. Physiol., 2006-05-01;207(2):364-73.
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA Development

IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation.
Authors: Lisignoli G, Cristino S, Toneguzzi S, Grassi F, Piacentini A, Cavallo C, Facchini A, Mariani E
Exp. Gerontol., 2004-04-01;39(4):659-65.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P